Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 92 clinical trials
Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

Eligible participants with locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck will be treated with reirradiation combined with anti-PD-1 mAb MK

head and neck carcinoma
mk-3475
squamous cell carcinoma
pembrolizumab
  • 25 views
  • 05 Apr, 2022
  • 4 locations
Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

The purpose of this study is to assess the safety and efficacy of pemetrexed + carboplatin + pembrolizumab (MK-3475) with lenvatinib (MK-7902/E7080) in patients with advanced nonsquamous non

  • 0 views
  • 24 Jul, 2022
  • 5 locations
Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer

The main purpose of this study is to assess the safety, tolerability and anti-tumor activity of the experimental study drug pembrolizumab (also known as Keytruda or MK-3475) in people with non

pembrolizumab
cancer chemotherapy
mk-3475
lung carcinoma
  • 0 views
  • 25 Feb, 2022
  • 1 location
A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer

positive breast cancer. The interventions involved in this study are: Pembrolizumab (MK-3475; Keytruda™) Nab-Paclitaxel (Abraxane

bisphosphonate
erbb2
paclitaxel
invasive breast cancer
endocrine therapy
  • 38 views
  • 23 Mar, 2022
  • 1 location
Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN

your body. The immunotherapy involved in this study is: MK-3475 (pembrolizumab or KEYTRUDA).

pembrolizumab
squamous cell carcinoma of head and neck
head and neck carcinoma
squamous cell carcinoma
carcinoma
  • 46 views
  • 28 Jan, 2022
  • 1 location
Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC (Replay)

Exploratory phase II trial of intravenous (IV) Pembrolizumab MK-3475 as second or further line with advanced Non-small cell Lung Cancer (NSCLC) who have failed to a prior treatment with anti

durvalumab
lung cancer
cancer
lung carcinoma
nivolumab
  • 9 views
  • 13 May, 2022
  • 17 locations
Pembrolizumab in Elderly Patients With Advanced Lung Cancer

This is a multi-center phase II trial of intravenous (IV) Pembrolizumab MK-3475 in subjects older than 70 years with advanced Non-small cell Lung Cancer (NSCLC) expressing Programmed death

pembrolizumab
mk-3475
epidermal growth factor receptor
lung carcinoma
epidermal growth factor
  • 3 views
  • 11 May, 2022
  • 12 locations
GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC

This is a single-arm, open-label, multi-site Phase I/IIa study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in combination with pembrolizumab (MK

hepatitis
antiviral therapy
hepatitis b surface antigen
antiviral drugs
measurable disease
  • 18 views
  • 11 May, 2022
  • 3 locations
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

interventions involved in this study are: Sacituzumab govitecan (IMMU-132) Pembrolizumab (Keytruda®; MK-3475)

brain metastases
liver metastasis
stage iv breast cancer
corticosteroids
measurable disease
  • 0 views
  • 08 Jul, 2022
  • 6 locations
Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (MK-3475-A31/KEYNOTE-A31) in Advanced or Metastatic Malignancy

fixed dose of anti-PD-1 antibody (Pembrolizumab/MK-3475) in the treatment of advanced or metastatic malignancy.

pembrolizumab
bone marrow procedure
monoclonal antibodies
primary cancer
  • 0 views
  • 16 Feb, 2022
  • 1 location